Leflunomide in combination therapy

Journal of Rheumatology

Volumn 31, Issue 7 SUPPL. 1, 2004, Pages 25-30

  Kalden, Joachim R ^a,h   Smolen, Josef S ^c   Emery, Paul ^d   Van Riel, Piet L C M ^b   Dougados, Maxime ^e   Strand, C Vibeke ^f   Breedveld, Ferdinand C ^g  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GENERAL HOSPITAL LINZ   (Austria)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e Hospital Cochin ^*  (France)

^f STANFORD UNIVERSITY   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Biologics; Combination drug therapy; Disease modifying antirheumatic drugs; Leflunomide; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ALOPECIA; ARTHRALGIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INFLUENZA; LIVER FUNCTION TEST; MEDICAL DECISION MAKING; MYALGIA; MYELODYSPLASIA; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFASALAZINE; TREATMENT OUTCOME;

EID: 2542618299     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Kremer J. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:14-26.
2. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
3. Dimitrova P, Skapendo A, Herrmann M, Schleyerbach R, Kalden J, Schulze-Koops H. Restriction of de novo pyrimide biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002;169:3392-9.
4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001;19:163-96.
5. Weinblatt M, Kremer J, Coblyn J, Maier A, Helfgott S, Morrell M. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
6. Kremer J, Genovese M, Cannon G, Caldwell J, Cush J, Furst D. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
7. Kremer J, Genvose M, Cannon G, Caldwell J, Cush J, Weisman M. Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis failing MTX monotherapy: an open label extension study [abstract]. Arthritis Rheum 2001;46 Suppl: S144.
8. Cohen S, Schiff M, Weaver A, Tesser J, Baraf H, Maestrello S. Leflunomide (LEF) as initial therapy with methotrexate (MTX) added for rheumatoid arthritis patients with active disease [abstract]. Arthritis Rheum 2002;46 Suppl:S352.
9. Dougados M, Combe B, van Riel P, Masek B, Brin S, Emery P. Efficacy and safety of leflunomide (LEF) in combination with sulfasalazine (SSZ) versus sulfasalazine in patients with rheumatoid arthritis: results from the RELIEF study [abstract]. Annual European Congress of Rheumatology, Stockholm, Sweden, June 12-15, 2002. [Internet]. Accessed February 13, 2004. Available from: http://www.eular.org/eular2002.cfm
10. Kiely P, Johnson D. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 2002;41:631-7.
11. Struppler C, Thies W, Schattenkirchner M, Kellner H. Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) patients [abstract]. Ann Rheum Dis 2002;61 Suppl:S388.
12. Schiff M, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in patients with rheumatoid arthritis [abstract]. Annual European Congress of Rheumatology, Stockholm, Sweden, June 12-15, 2002. [Internet]. Accessed February 13, 2004. Available from: http://www.eular.org/eular2002.cfm
13. Patel S, Bergen W, Kraemer A, Keenan G. Efficacy and safety of Remicade (infliximab) and Arava (leflunomide) in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S189.
14. Hansen K, Cush J, Singhal A, Cooley D, Patel S, Genovese M. The safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S84.